Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Authors:
- Darren GriffithDGDarren Griffith
- James P. ParkerJPJames P. Parker
- Celine J. MarmionCMCeline J. Marmion
- 1 June 2010
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 10 (5) , 354-370
Abstract
Historically, DNA has been the target for many metal-based anti-cancer drugs, but drawbacks of prevailing therapies have stimulated the search for new molecular targets which may present unique opportunities for therapeutic exploitation. Enzyme inhibition has recently been identified as an alternative and significant target. The pursuit of novel metallodrug candidates that selectively target enzymes is now the subject of intense investigation in medicinal bioinorganic chemistry and chemical biology. In the field of drug design, it is recognised by many that exploiting the structural and chemical diversity of metal ions for the identification of potential hit and lead candidates can dramatically increase the number of possible drug candidates that may be added to the already abundant armoury of chemotherapeutic agents. This review will focus on recent key advancements in enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics. The enormous clinical success of classical platinum drugs, amongst others, coupled with the wealth of knowledge accumulated in recent years on enzyme structure and function, has undoubtedly been the impetus behind the development of new metallodrug candidates with enzyme inhibitory properties. Recent trends in this field will be reviewed with a particular emphasis on metal complexes that inhibit protein and lipid kinases, matrix metalloproteases, telomerases, topoisomerases, glutathione-Stransferases, and histone deacetylases.Keywords
This publication has 78 references indexed in Scilit:
- Rational Design of an Organometallic Glutathione Transferase InhibitorAngewandte Chemie International Edition, 2009
- On the Hydrolysis Mechanism of the Second‐Generation Anticancer Drug CarboplatinChemistry – A European Journal, 2007
- Organometallic Ruthenium Inhibitors of Glutathione‐S‐Transferase P1‐1 as Anticancer DrugsChemMedChem, 2007
- Studies of a Cobalt(III) Complex of the MMP Inhibitor Marimastat: A Potential Hypoxia‐Activated ProdrugChemistry – A European Journal, 2007
- Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted ChemotherapyEuropean Journal of Inorganic Chemistry, 2006
- Ruthenium Half‐Sandwich Complexes Bound to Protein Kinase Pim‐1Angewandte Chemie International Edition, 2006
- Metalloproteinases and their inhibitors in tumor angiogenesisInternational Journal of Cancer, 2005
- Porphyrin Derivatives for Telomere Binding and Telomerase InhibitionChemBioChem, 2005
- Synthesis and Characterization of Platinum(II) Complexes of Diethyl [(Methylsulfinyl)methyl]phosphonate: Potential Drugs against Bone TumorsEuropean Journal of Inorganic Chemistry, 2004
- A novel platinum compound inhibits telomerase activity in vitro and reduces telomere length in a human hepatoma cell lineInternational Journal of Cancer, 2003